Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Chang Chen, Jianying Huang, Ping Yin, Yi Zhang, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Jingyi Zhang, View ORCID ProfileXinghuan Wang
doi: https://doi.org/10.1101/2020.03.17.20037432
Chang Chen
1Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
2Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianying Huang
1Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
3Wuhan Leishenshan Hospital, Wuhan, Hubei, 430000, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ping Yin
4Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Zhang
5Center for Life Sciences, Peking University, Beijing, 100871, China
6Euler Technology, ZGC Life Sciences Park, Beijing, 102200, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhenshun Cheng
7Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianyuan Wu
1Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
3Wuhan Leishenshan Hospital, Wuhan, Hubei, 430000, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Song Chen
8Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongxi Zhang
9Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Chen
1Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
3Wuhan Leishenshan Hospital, Wuhan, Hubei, 430000, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mengxin Lu
8Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongwen Luo
8Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingyi Zhang
10Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei, 430033, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinghuan Wang
1Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
3Wuhan Leishenshan Hospital, Wuhan, Hubei, 430000, China
5Center for Life Sciences, Peking University, Beijing, 100871, China
11Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xinghuan Wang
  • For correspondence: wangxinghuan{at}whu.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance No clinically proven effective antiviral strategy exist for the emerging epidemic Coronavirus Disease 2019 (COVID-19).

Objective To compare the efficacy and safety of favipiravir and arbidol to treat COVID-19 patients.

Design Prospective, multicenter, open-label, randomized superiority trial in February, 2020.

Setting Multicenter study.

Participants Patients with confirmed COVID-19 admitted to 3 hospitals from Feb. 20, 2020 to Mar. 12, 2020.

Interventions Conventional therapy + favipiravir or arbidol.

Main Outcomes and Measures The primary outcome was clinical recovery rate of day 7. Duration of fever, cough relief latency, and auxiliary oxygen therapy or noninvasive mechanical ventilation rate were the secondary outcomes. The patients with chest CT imaging and laboratory-confirmed COVID-19 infection, aged 18 years or older were randomly assigned to receive favipiravir or arbidol. Safety data were collected for further follow-up for a week.

Results 120 patients were assigned to favipiravir group (116 assessed) and 120 to arbidol group (120 assessed). In full analysis set (FAS) cohort, clinical recovery rate of day 7 does not significantly differ between the favipiravir group (61.20% (71/116)) and the arbidol group (51.67% (62/120)) (P=0.1396, OR: 1.47). The latency to fever reduction and cough relief in favipiravir group was significantly shorter than that in arbidol group (both P<0.0001). No statistical difference was observed of auxiliary oxygen therapy or noninvasive mechanical ventilation rate (both P>0.05). The most frequently observed favipiravir-associated adverse events were abnormal LFT (10/116, 8.62%, OR: 0.86, P=0.7156), psychiatric symptom reactions (5/116, 4.31%, OR: 5.17, P=0.1149), digestive tract reactions (16/116, 13.79%, OR: 0.97, P=0.6239) and raised serum uric acid (16/116, 13.79%, OR: 5.52, P=0.0014).

Conclusions and Relevance Among patients with confirmed COVID-19, favipiravir, compared to arbidol, did not significantly improve the clinically recovery rate by 7 days. Favipiravir significantly improved time-to-relief for fever and cough. Antiviral-associated adverse effects associated with favipiravir are mild and manageable.

Trial Registration This study is registered with Chictr.org.cn, number ChiCTR2000030254.

Question How about the efficacy and safety of favipiravir to treat COVID-19 patients?

Findings Among patients with confirmed COVID-19, favipiravir, compared to arbidol, did not significantly improve the clinically recovery rate by 7 days. Favipiravir treatment significantly improved time-to-relief for fever and cough, and is associated with manageable adverse effects.

Meaning For COVID-19 patients, favipiravir is a safe and at least similarly effective option compared to arbidol.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

This study is registered with Chictr.org.cn, number ChiCTR2000030254.

Funding Statement

This work was supported by the National Key Research and Development Program of China (2020YFC0844400).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

With the permission of the corresponding author, we can provide participant data, statistical analysis.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 08, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chang Chen, Jianying Huang, Ping Yin, Yi Zhang, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Jingyi Zhang, Xinghuan Wang
medRxiv 2020.03.17.20037432; doi: https://doi.org/10.1101/2020.03.17.20037432
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chang Chen, Jianying Huang, Ping Yin, Yi Zhang, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Jingyi Zhang, Xinghuan Wang
medRxiv 2020.03.17.20037432; doi: https://doi.org/10.1101/2020.03.17.20037432

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13340)
  • Forensic Medicine (19)
  • Gastroenterology (896)
  • Genetic and Genomic Medicine (5130)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3252)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1013)
  • Infectious Diseases (except HIV/AIDS) (14611)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4899)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (879)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (538)
  • Pediatrics (1297)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4192)
  • Public and Global Health (7482)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (545)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)